HeartBeam

Executive Summary

HeartBeam is a digital health company pioneering remote cardiac monitoring with its flagship product, AIMIGo™, a credit card-sized, cable-free device that synthesizes a medical-grade 12-lead ECG. Designed for patient use at home during symptoms, the device transmits heart signal data to the cloud for physician review, enabling timely detection and triage of cardiac events such as arrhythmias and heart attacks. Founded in 2015 and headquartered in Santa Clara, California, HeartBeam addresses the critical gap in outpatient cardiac monitoring, offering a portable alternative to traditional Holter monitors and resting ECGs. With the rising prevalence of cardiovascular diseases and growing demand for telehealth solutions, HeartBeam's technology has the potential to improve outcomes by reducing time to diagnosis and enabling proactive management of cardiac conditions. The company operates in a competitive landscape but differentiates through its unique ability to provide a complete 12-lead view from a compact device, which is well-suited for integration into virtual care platforms. While HeartBeam is currently private and has not disclosed funding or valuation, its product addresses a substantial market opportunity, especially given the increasing focus on decentralized clinical trials and remote patient monitoring. The investment thesis hinges on regulatory clearance and commercial adoption, with early validation from clinical studies likely to drive partnerships with healthcare providers and payers.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for AIMIGo70% success
• Q3 2026Publication of Pivotal Clinical Study Results60% success
• H1 2027Strategic Partnership or Distribution Agreement50% success